| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
C8 Ceramide targets multiple cellular pathways, including apoptosis, PKC, and autophagy. It stimulates ceramide-activated protein kinase and can induce apoptosis in various cancer cell lines. It also modulates reactive oxygen species (ROS) levels by regulating the switch of SOD1 and SOD2. C8 Ceramide can induce necrosis-like cell death in certain cell types.
|
|---|---|
| ln Vitro |
Tumor cell growth is irreversibly reduced and morphological alterations are induced by C8-ceramide (3 μM; 48 hours) [1]. In human cervical carcinoma cells, C8-ceramide can cause necrosis-like cell death, but it does not cause the molecular marker of apoptosis, PARP, to be cleaved in a caspase-dependent manner [1]. In NSCLC H1299 cells, C8-ceramide may elevate endogenous ROS levels (10-30 µM; 24 hours), inhibit proliferation (10-50 µM; 24 hours), and therefore induce apoptosis (10-50 µM; 48 hours) [2].
In vitro, C8 Ceramide (3 μM; 48 hours) irreversibly reduces tumor-cell proliferation and induces morphological changes in CALO, INBL, and HeLa cells. It induces necrosis-like cell death but does not induce caspase-dependent cleavage of PARP in human cervical tumor cells. In NSCLC H1299 cells, it increases endogenous ROS levels (10-30 μM; 24 hours) and causes antiproliferation (10-50 μM; 24 hours) with an IC50 of 22.9 μM, and triggers apoptosis (10-50 μM; 48 hours). |
| ln Vivo |
In mice infected with a virus, C8-ceramide (0.1 mg/kg; administered intravenously) increases CD8+ and CD4+ T cell responses to infection [3].
C8 Ceramide has been shown to stimulate dendritic cells to promote T cell responses to viral infections. As a cell-permeable ceramide analog, it can modulate sphingolipid signaling pathways in vivo. Specific in vivo efficacy data, including dosing regimens and animal models, are not extensively provided in the available literature. The compound's ability to induce apoptosis suggests potential for anticancer therapy. |
| Enzyme Assay |
In vitro enzyme assays for C8 Ceramide involve measuring ceramide-activated protein kinase activity. The enzyme is incubated with ceramide substrates and varying concentrations of C8 Ceramide. Kinase activity is measured by quantifying phosphorylation of target proteins using radiolabeled ATP or by using antibody-based detection. Specific protocols are not extensively documented in the available literature.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: CALO cells, INBL cells, HeLa cells Tested Concentrations: 3 μM Incubation Duration: 48 hrs (hours) Experimental Results: The number of tumor cells was Dramatically diminished. Cell proliferation assay[2] Cell Types: H1299 Cell Tested Concentrations: 10 µM, 20 µM, 30 µM, 40 µM, 50 µM Incubation Duration: 24 hrs (hours) Experimental Results: diminished cell proliferation rate in a dose-dependent manner, IC50 22.9 µM. Cell cycle analysis[2] Cell Types: H1299 Cell Tested Concentrations: 10 µM, 20 µM, 30 µM, 40 µM, 50 µM Incubation Duration: 24 hrs (hours) Experimental Results: Causes G1 arrest. Apoptosis analysis[2] Cell Types: H1299 Cell Tested Concentrations: 10 µM, 20 µM, 30 µM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Increased levels of cleaved caspase-3. For in vitro cell-based assays, cancer cell lines such as HeLa, H1299, CALO, and INBL cells are cultured and treated with C8 Ceramide at various concentrations (3-50 μM) for 24-48 hours. Cell proliferation is assessed using MTT or similar assays. Apoptosis is measured by Annexin V/PI staining, caspase activity assays, or by assessing PARP cleavage. ROS levels are measured using fluorescent probes. Cell cycle analysis is performed by propidium iodide staining and flow cytometry. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice, lymphocytic choriomeningitis virus infection [3]
Doses: 0.1 mg/kg Route of Administration: Intranasal administration Experimental Results: Enhanced lung CD8+ T cell response to influenza. In vivo animal studies for C8 Ceramide would typically use tumor xenograft models in immunodeficient mice. Cancer cells are implanted subcutaneously, and tumors are allowed to establish. C8 Ceramide is administered intraperitoneally or intravenously at doses determined from pharmacokinetic and toxicity studies. Tumor volume is measured twice weekly. Apoptosis and signaling pathway changes are assessed in tumor tissues by immunohistochemistry and Western blot. |
| ADME/Pharmacokinetics |
C8 Ceramide has a molecular formula of C26H51NO3 and a molecular weight of 425.69. It is soluble in DMSO at ≥100 mg/mL (234.91 mM). It should be stored at -20°C under nitrogen, and in solvent at -80°C for 6 months or -20°C for 1 month. Detailed pharmacokinetic parameters are not extensively characterized.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for C8 Ceramide are not extensively provided in the available literature. As a cell-permeable ceramide analog, it can induce apoptosis and may have cytotoxic effects at higher concentrations. The compound is for research use only and is not for human or clinical use. Standard toxicology assessments would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
N-Octaylsphingosine is an N-acylsphingosine in which the ceramide N-acyl group is designated as octayl. It is functionally related to octanoic acid.
C8 Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of natural ceramide. It stimulates ceramide-activated protein kinase and induces apoptosis. It has antiproliferative properties and can act as a chemotherapeutic agent. C8 Ceramide stimulates dendritic cells to promote T cell responses to viral infections. It modulates ROS levels and induces G1 arrest in cancer cells. No approved therapeutic status is reported. |
| Molecular Formula |
C26H51NO3
|
|---|---|
| Molecular Weight |
425.69
|
| Exact Mass |
425.386
|
| CAS # |
74713-59-0
|
| PubChem CID |
5702614
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
595.5±50.0 °C at 760 mmHg
|
| Melting Point |
68-70°C
|
| Flash Point |
313.9±30.1 °C
|
| Vapour Pressure |
0.0±3.8 mmHg at 25°C
|
| Index of Refraction |
1.482
|
| LogP |
9.09
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
30
|
| Complexity |
398
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCCCCCC/C=C/[C@H]([C@H](CO)NC(=O)CCCCCCC)O
|
| InChi Key |
APDLCSPGWPLYEQ-WRBRXSDHSA-N
|
| InChi Code |
InChI=1S/C26H51NO3/c1-3-5-7-9-10-11-12-13-14-15-16-18-19-21-25(29)24(23-28)27-26(30)22-20-17-8-6-4-2/h19,21,24-25,28-29H,3-18,20,22-23H2,1-2H3,(H,27,30)/b21-19+/t24-,25+/m0/s1
|
| Chemical Name |
N-[(E,2S,3R)-1,3-dihydroxyoctadec-4-en-2-yl]octanamide
|
| Synonyms |
N-Octanoyl-D-erythro-Sphingosine; C8-Ceramide; C8 Ceramide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~234.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3491 mL | 11.7456 mL | 23.4913 mL | |
| 5 mM | 0.4698 mL | 2.3491 mL | 4.6983 mL | |
| 10 mM | 0.2349 mL | 1.1746 mL | 2.3491 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
